Two faces of inflammation: An immunopharmacological view

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 1, 2014, Pages 2-6

  Moilanen, Eeva ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANTIINFLAMMATORY AGENT; AUTOANTIBODY; ICOSANOID; ION CHANNEL; PHOSPHOTRANSFERASE; PROTEIN KINASE;

CLINICAL PHARMACOLOGY; DRUG RESEARCH; ELECTRIC POTENTIAL; EOSINOPHIL; IMMUNOPHARMACOLOGY; INFLAMMATION; OBESITY; PRIORITY JOURNAL; REVIEW;

ADIPOKINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; EICOSANOIDS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; NEOPLASMS; OBESITY; PAIN; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84890578016     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12180     Document Type: Review

References (58)

1. Turvey SE, Broide DH. Innate immunity. J Allergy Clin Immunol 2010;125:S24-32.
2. Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol 2010;125:S33-40.
3. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41.
4. Willemze A, Trouw LA, Toes RE, Huizinga TW. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012;8:144-52.
5. Cerqueira CF, Klareskog L, Jakobsson PJ. Neutralization of anticitrullinated protein antibodies in rheumatoid arthritis - a way to go? Basic Clin Pharmacol Toxicol 2013;114:13-7.
6. Kita H. Eosinophils: multifunctional and distinctive properties. Int Arch Allergy Immunol 2013;161(Suppl 2):3-9.
7. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008;38:709-50.
8. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991;147:3490-5.
9. Zhang X, Moilanen E, Kankaanranta H. Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol 2000;406:325-32.
10. Ilmarinen P, Kankaanranta H. Eosinophil apoptosis as a therapeutic target in allergic asthma. Basic Clin Pharmacol Toxicol 2013;114:109-17.
11. Dovizio M, Alberti S, Guillem-Llobat P, Patrignani P. Role of platelets in inflammation and cancer: novel therapeutic strategies. Basic Clin Pharmacol Toxicol 2013;114:118-27.
12. Blalock JE, Smith EM. Conceptual development of the immune system as a sixth sense. Brain Behav Immun 2007;21:23-33.
13. Kraneveld AD, de Theije CG, van Heesch F, Borre Y, de Kivit S, Olivier B et al. The neuro-immune axis: prospect for novel treatments of mental disorders. Basic Clin Pharmacol Toxicol 2013;114:128-36.
14. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol 1971;231:237-9.
15. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
16. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
17. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
18. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52:1628-36.
19. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79.
20. Wang M, FitzGerald GA. Cardiovascular biology of microsomal prostaglandin E synthase-1. Trends Cardiovasc Med 2010;20:189-95.
21. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999;96:7220-5.
22. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 2003;100:9044-9.
23. Kojima F, Kapoor M, Yang L, Fleishaker EL, Ward MR, Monrad SU et al. Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice. J Immunol 2008;180:8361-8.
24. Korotkova M, Jakobsson PJ. Characterization of mPGES-1 Inhibitors. Basic Clin Pharmacol Toxicol 2013;114:64-9.
25. Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, Brash AR et al. The structure of human 5-lipoxygenase. Science 2011;331:217-9.
26. Ochs MJ, Sorg BL, Pufahl L, Grez M, Suess B, Steinhilber D. Post-transcriptional regulation of 5-lipoxygenase mRNA expression via alternative splicing and nonsense-mediated mRNA decay. PLoS ONE 2012;7:e31363.
27. Bruno A, Tacconelli S, Patrignani P. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives. Basic Clin Pharmacol Toxicol 2013;114:56-63.
28. Ochs MJ, Suess B, Steinhilber D. 5-Lipoxygenase mRNA and protein isoforms. Basic Clin Pharmacol Toxicol 2013;114:78-82.
29. Steinhilber D, Hofmann B. Recent advances in the search for novel 5-Lipoxygenase inhibitors. Basic Clin Pharmacol Toxicol 2013;114:70-7.
30. Meirer K, Steinhilber D, Proschak E. Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. Basic Clin Pharmacol Toxicol 2013;114:83-91.
31. Ochs MJ, Steinhilber D, Suess B. MicroRNAs - novel therapeutic targets of eicosanoid signalling. Basic Clin Pharmacol Toxicol 2013;114:92-6.
32. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-34.
33. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36:503-14.
34. Laurence A, Pesu M, Silvennoinen O, O'Shea J. JAK kinases in health and disease: an update. Open Rheumatol J 2012;6:232-44.
35. Aittomaki S, Pesu M. Therapeutic targeting of the JAK/STAT pathway. Basic Clin Pharmacol Toxicol 2013;114:18-23.
36. Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta 2011;1813:1619-33.
37. Korhonen R, Moilanen E. MAP Kinase Phosphatase-1 as an inflammatory factor and drug target. Basic Clin Pharmacol Toxicol 2013;114:24-36.
38. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 2006;203:1883-9.
39. Nieminen R, Korhonen R, Moilanen T, Clark AR, Moilanen E. Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs. Arthritis Rheum 2010;62:1650-9.
40. Korhonen R, Hommo T, Keranen T, Laavola M, Hamalainen M, Vuolteenaho K et al. Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1. Br J Pharmacol 2013;169:1525-36.
41. Leppanen T, Tuominen RK, Moilanen E. Protein kinase C and its inhibitors in the regulation of inflammation. Inducible nitric oxide synthase as an example. Basic Clin Pharmacol Toxicol 2013;114:37-43.
42. Lee MR, Duan W, Tan SL. Protein kinase C isozymes as potential therapeutic targets in immune disorders. Expert Opin Ther Targets 2008;12:535-52.
43. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012;11:937-57.
44. Lai WQ, Chia FL, Leung BP. Sphingosine kinase and sphingosine-1-phosphate receptors: novel therapeutic targets of rheumatoid arthritis? Future Med Chem 2012;4:727-33.
45. Schwalm S, Pfeilschifter J, Huwiler A. Sphingosine-1-phosphate: a Janus-faced mediator of fibrotic diseases. Biochim Biophys Acta 2013;1831:239-50.
46. Schwalm S, Pfeilschifter J, Huwiler A. Targeting the Sphingosine Kinase/Sphingosine 1-Phosphate pathway to treat chronic inflammatory kidney diseases. Basic Clin Pharmacol Toxicol 2013;114:44-9.
47. Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: a clinical perspective. Br J Pharmacol 2013; DOI: 10.1111/bph.12414. [Epub ahead of print].
48. Nilius B, Appendino G, Owsianik G. The transient receptor potential channel TRPA1: from gene to pathophysiology. Pflugers Arch 2012;464:425-58.
49. Bautista DM, Pellegrino M, Tsunozaki M. TRPA1: a gatekeeper for inflammation. Annu Rev Physiol 2013;75:181-200.
50. Moilanen LJ, Laavola M, Kukkonen M, Korhonen R, Leppanen T, Hogestatt ED et al. TRPA1 contributes to the acute inflammatory response and mediates carrageenan-induced paw edema in the mouse. Sci Rep 2012;2:380.
51. Caceres AI, Brackmann M, Elia MD, Bessac BF, del Camino D, D'Amours M et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc Natl Acad Sci U S A 2009;106:9099-104.
52. Koivisto A, Chapman H, Jalava N, Korjamo T, Saarnilehto M, Lindstedt K et al. TRPA1: a transducer and amplifier of pain and inflammation. Basic Clin Pharmacol Toxicol 2013;114:50-5.
53. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
54. Scotece M, Conde J, Vuolteenaho K, Koskinen A, Lopez V, Gomez-Reino J et al. Adipokines as drug targets in joint and bone disease. Drug Discov Today 2013; DOI: 10.1016/j.drudis.2013.07.012. [Epub ahead of print].
55. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
56. Scotece M, Conde J, Lopez V, Lago F, Pino J, Gomez-Reino JJ et al. Adiponectin and leptin: new targets in inflammation. Basic Clin Pharmacol Toxicol 2013;114:97-102.
57. Vuolteenaho K, Koskinen A, Moilanen E. Leptin - a link between obesity and osteoarthritis. Applications for Prevention and Treatment. Basic Clin Pharmacol Toxicol 2013;114:103-8.
58. Knowles RG. Development of anti-inflammatory drugs - the research and development process. Basic Clin Pharmacol Toxicol 2013;114:7-12.